QUICK ANSWER · AEO / GEO
Ovagen is linked to the Glu-Asp-Leu (EDL) tripeptide in research-group literature, but that name does not authenticate a supplier product. It must be distinguished from the unrelated ovine FSH preparation also called Ovagen. Verified EDL studies concern renal cell/tissue cultures, rat kidney-injury models and computational DNA docking. Cell biomarkers and animal kidney signals do not establish human liver repair, kidney treatment, anti-aging benefit or administration safety. No randomised human trial of exact EDL was verified in the reviewed sources. Class E denotes unresolved exact-product identity and authorisation; Grade E denotes preclinical evidence. Registration in Thailand, the U.S., EU and UK remains unverified for the supplier product.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.
Read original excerpts (Thai / mixed language)
- หลักฐานที่ทบทวนเป็น preclinical และใช้สารหรือแบบจำลองที่ระบุ ไม่พบการทดลองมนุษย์แบบสุ่มของ exact EDL ที่ตรวจยืนยันได้จากแหล่งเหล่านี้ การเชื่อมชื่อ Ovagen–EDL ในตารางวิจัยไม่ใช่การรับรองผลิตภัณฑ์ และคำว่า hepatoprotection ในบททบทวนไม่แทนผลลัพธ์ผู้ป่วยตับ ห้ามนำงาน Ovagen/FSH ในสัตว์มาอ้างเป็นหลักฐานของ EDL
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- 2022 research-group paper · Table 2 identifies Ovagen (EDL); modelling/review, not a human efficacy trial
- PMID 18325004 · Ovagen as ovine FSH in porcine oocyte culture — a different substance
- PMID 8265802 · Veterinary FSH preparations sharing the Ovagen name
- Renal cell ageing · PMID 25946838 (2014)
- Kidney tissue renewal · PMID 26033601 (2015)
- Cisplatin kidney-injury model · PMID 26515176 (2015)
- Acute kidney injury models · PMID 28744634 (2017)
- DNA docking hypothesis · PMID 27909961 (2016)
FAQ · ANSWER ENGINE
Frequently asked questions
What is Ovagen (EDL)?
Ovagen (EDL) is described pharmacologically as Experimental Glu-Asp-Leu tripeptide; renal cell and animal research. Ovagen is linked to the Glu-Asp-Leu (EDL) tripeptide in research-group literature, but that name does not authenticate a supplier product. It must be distinguished from the unrelated ovine FSH preparation also called Ovagen. Verified EDL studies concern renal cell/tissue cultures, rat kidney-injury models and computational DNA docking. Cell biomarkers and animal kidney signals do not establish human liver repair, kidney treatment, anti-aging benefit or administration safety. No randomised human trial of exact EDL was verified in the reviewed sources. Class E denotes unresolved exact-product identity and authorisation; Grade E denotes preclinical evidence. Registration in Thailand, the U.S., EU and UK remains unverified for the supplier product.
Does Ovagen (EDL) have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Ovagen (EDL) approved everywhere?
No global conclusion should be inferred. PrimeCore Class E must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.